Psoriasis

Results of methotrexate dosing for patients with psoriasis were published in the Journal of the American Medical Association Dermatology.

Arcutis Biotherapeutics’ roflumilast cream will provide relief to patients aged 12 years or older diagnosed with plaque psoriasis.

Paller discusses the findings of the clinical trial examining the long-term effects of ixekizumab for treating psoriasis in children.

A study published in JAAD International examined the association between psoriasis and adverse pregnancy outcomes (APOs) and found that providers should be on the lookout for ectopic pregnancies (EP) in this population.

From pediatric dermatology quizzes to the latest news in telederm to practical pearls on atopic dermatitis, alopecia, and vitiligo, there’s a lot going on at the SPD 2022 47th Annual Meeting, this year in Indianapolis, Indiana.

Click here to answer this week's poll.

Arthur Kavanaugh, MD, a professor of medicine and director of the Center for Innovative Therapy (CIT) at UC San Diego in California, gives his thoughts on the treatments for psoriatic arthritis, the comorbidities that have to be considered, and more.

A new study aimed to evaluate the differences in the immunohistochemical staining (IHS) in patients with palmoplantar pustulosis and determine whether they can be divided into two distinct groups based on their histopathological profiles

A recent study dove into how psoriasis and sleep interruptions are related to each other.

At the 2022 SDPA Annual Summer Meeting, Lisa Swanson, MD, shared some fascinating patient presentations in pediatric dermatology.

At the 2022 National Infusion Center Association Annual Conference, Kelly Gordon, PharmD, answered why diagnosing GPP is so difficult and what to look for to optimize patient care.

Education, honesty, and communication skills are key for both patient and dermatologist when it comes to creating treatment regimens.

In a video with Dermatology Times®, James Q. Del Rosso, DO, discusses his presentation “What’s News in the Medicine Chest” at the current 2022 Fall Clinical Dermatology Conference for PAs & NPs.

In a hard-hitting session from the 2022 Fall Clinical Dermatology Conference for PAs & NPs, April Armstrong, MD, MPH, dove into PAD technology and future innovations in psoriasis treatment.

Dermavant’s new topical treatment for plaque psoriasis in adults was approved by the FDA this morning.

Lifestyle behaviors, such as body mass index and smoking, were shown to have a stronger association with psoriasis, regardless of genetic risk.

The risks of certain comorbid conditions varied between the 2 groups of patients.

In this week’s Pointers with Dr Portela, the 208SkinDoc hosts a podcast called, “Between Two Derms.” This week he covers cases in the clinic, psoriasis at the Met Gala and more.

UCB announced the FDA issued a CRL that stated that the FDA cannot approve the BLA in its current form.

In the world of pediatric dermatology, many skin conditions can have parents concerned about their children’s condition. Lisa Swanson, MD, explains how to better address their questions at the 3rd Annual Society of Dermatology Nurse Practitioners Symposium.

At the opening session of the Society of Dermatology Nurse Practitioners Annual Symposium, Kathleen Haycraft, DNP, FNP-BC, DCNP, FAANP, delved into the revolutionary and evolutionary advances shaping dermatology in 2022.

In this video interview, Andrew Blauvelt, MD, MBA, dermatologist and clinical researcher at the Oregon Medical Research Center, highlights his key takeaways from his presentation at the Annual Society of Dermatology Nurse Practitioners Symposium, held April 22-23, in Nashville, Tennessee.

Arcutis Biotherapeutics announced news of its topical roflumilast foam’s trial on safety and efficacy of treatment in scalp and body psoriasis.

A recent study showed that men with psoriasis have larger EAT-V than those without the skin disease.

As innovation in dermatology continues, so do questions on the efficacy of cannabinoid use for psoriasis, among other skin diseases.

The results from the Evelo Biosciences EDP1815 treatment provide the first demonstration in a phase 2 trial of the safety and efficacy of an orally-administered, gut-restricted SINTAX medicine.

Nearly all survey takers reported wanting topical treatment options that are more effective, not steroids, and simpler to use.

New data shows complete skin clearance using bimekizumab in moderate to severe plaque psoriasis open-label extension study.

The company announced the results from its long-term extension study, highlighting improved efficacy outcomes, quality of life, and tolerability data.

In a recent study from the Journal of the American Academy of Dermatology, investigators assessed symptoms, disease burden, and use of analgesics in patients with or without psoriatic arthritis.